Bioceres Revenue Was $77.5 Million in Fiscal 2026 First Quarter, Down 17%
Key Facts
Bioceres Crop Solutions’ fiscal 2027 first-quarter results announcement or figures could not be verified through a reliable open source. As a result, no confirmed figures are available to report the period’s performance attributed in the news report to an announcement on November 11, 2026. In the latest documented first-quarter results available, the company reported revenue of $77.5 million in fiscal 2026’s first quarter. That represented a 17% year-over-year decline. The performance came during a fiscal year marked, according to the company, by challenges related to litigation with some creditors.
Fiscal 2026 first-quarter revenue was spread across three businesses, led by crop protection, which generated $39.9 million. Seeds and integrated products generated $12.6 million, while crop nutrition revenue was $25.1 million. Year over year, revenue fell 16% in crop protection, 37% in seeds and integrated products, and 2% in crop nutrition. The declines therefore varied by business, with the largest relative drop in seeds and integrated products. These prior figures show the revenue mix that can be used while awaiting verified fiscal 2027 first-quarter figures.
Gross profit fell to $36.2 million in fiscal 2026’s first quarter, from $37.5 million in the year-earlier period. But gross margin rose to 46.7% from 40.2%, according to the company’s results. Bioceres posted a net loss of $7.5 million, compared with a loss of $6.2 million a year earlier. Adjusted EBITDA, meanwhile, rose to $13.6 million, up 61% year over year. The period’s indicators show improved margin and adjusted earnings alongside a wider net loss, without providing evidence of the fiscal 2027 first-quarter result.
For fiscal 2026, revenue from continuing operations was $238.3 million, down 18% from the prior year. The loss from continuing operations was $54.4 million, compared with a loss of $49.1 million in fiscal 2025. In its annual results presentation, the company said the year was marked by the ongoing dispute with some creditors and its consequences for the business. It said its priorities included focusing on its core capabilities, reducing its cost structure and strengthening operating discipline. This background places the financial pressures and dispute in the context in which the company entered fiscal 2027.
The annual report disclosed total debt of $229.2 million as of June 30, 2026. Of that amount, $169.2 million was due during the fiscal year ending June 30, 2027. The report also said a New York court issued a judgment of about $110.1 million in favor of securities holders on September 23, 2026. The judgment was under appeal when the annual report was prepared. These obligations and the court judgment add pressure to the liquidity and capital position, which management said was a priority.
Fiscal 2026 third-quarter results showed revenue of $39.4 million and a net loss of $10.0 million. These figures are an earlier quarterly comparison in the company’s record ahead of fiscal 2027’s first quarter and do not replace the unverified new-quarter data. In the stock market, the company’s shares, traded under the ticker BIOX, closed at $0.2145 on November 10, 2026, according to available EL7 data. No verified opening, high or low prices for that session are available in the evidence. Reporting on the stock’s performance that day is therefore limited to its closing price.
As the company entered fiscal 2027, the CEO said its focus was on improving the performance of its continuing businesses and strengthening cash generation. He added that priorities included maintaining discipline in costs and working capital, and addressing the capital structure and liquidity. Management said its goal was to "improve the performance of our continuing businesses and generate cash." No verified fiscal 2027 first-quarter results were available to compare with these priorities or with results from earlier periods. Those results remain necessary to assess the new period’s performance against management’s stated goals.